Lirafugratinib had Breakthrough Therapy, Priority Review, and Orphan Drug designations stacked against it before Tuesday’s FDA approval, and it still had to prove itself against an established second-line option in a niche defined by a single genomic alteration. Now it has both: the agency approved Lyrfigtu (lirafugratinib) on September 23 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma carrying an FGFR2 fusion or other rearrangement. Elevar Therapeutics, a majority-owned subsidiary of HLB Co., Ltd., holds the approval.
The approval rests on the REFOCUS trial (NCT04526106), a Phase 2 study that served as the regulatory basis for the submission. FGFR2 fusions occur in roughly 15% of intrahepatic cholangiocarcinomas, a fraction that drops below 3% in other bile duct subsites, so the eligible population at any given site is small. That patient volume reality shapes commercial expectations: pemigatinib (Pemazyre, Incyte) has held accelerated approval in this same setting since April 2020, giving it a six-year head start on physician familiarity and formulary positioning.
What Elevar needs to establish now is whether lirafugratinib’s efficacy data offer oncologists a clinically meaningful reason to switch their defaults. The REFOCUS dataset will carry that argument or fail to make it. Breakthrough designation signals FDA saw early evidence worth expediting, but it does not settle the comparative question that payers and tumor boards will ask when two agents target the same alteration in the same line of therapy. Molecular testing practices matter here too: intrahepatic CCA patients who reach second-line treatment have generally already had comprehensive profiling, so FGFR2 status is rarely the diagnostic bottleneck at the point of prescribing.
The concrete marker to watch is how quickly major cancer centers update their institutional pathways for FGFR2-rearranged CCA. Pathway inclusion, not approval date, determines whether a new agent reaches its eligible patients or sits as a rarely selected alternative to an entrenched standard.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
